We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+13.25%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.05B
AUM Growth
+$53.4M
Cap. Flow
-$44.1M
Cap. Flow %
-4.2%
Top 10 Hldgs %
70.43%
Holding
48
New
17
Increased
6
Reduced
6
Closed
15

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$50.1M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$35M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$25.1M
4
UBX
Unity Biotechnology
UBX
+$24.6M
5
KZR
Kezar Life Sciences
KZR
+$22.2M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$49.8M
2
WVE icon
Wave Life Sciences
WVE
+$45M
3
ASND icon
Ascendis Pharma A/S
ASND
+$23.6M
4
APLS
Apellis Pharmaceuticals
APLS
+$23.4M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 87.08%
2 Miscellaneous 12.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYNB
1
Kyntra Bio
KYNB
$32.5M
$126M 12.02%
80,690
+593
+0.7% +$773K
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$682M
$120M 11.38%
7,462,587
+435,201
+6% +$6.44M
ASMB icon
3
Assembly Biosciences
ASMB
$694M
$115M 10.99%
245,264
– –
ASND icon
4
Ascendis Pharma A/S
ASND
$16.3B
$97.4M 9.27%
1,464,067
-358,508
-20% -$23.6M
KURA icon
5
Kura Oncology
KURA
$1.13B
$71.1M 6.77%
3,904,675
+137,823
+4% +$2.33M
MDGL icon
6
Madrigal Pharmaceuticals
MDGL
$12.3B
$55.8M 5.31%
+199,500
New +$35M
CELG
7
CALL
DELISTED
Celgene Corp
CELG
$46.5M 4.42%
585,000
+200,000
+52% +$16.6M
SRRK icon
8
Scholar Rock
SRRK
$7.04B
$41.7M 3.97%
+2,671,161
New +$50.1M
DRNA
9
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$36.3M 3.45%
2,961,147
-1,803,300
-38% -$22.7M
MGNX icon
10
MacroGenics
MGNX
$263M
$30M 2.85%
1,450,606
– –
ASND icon
11
CALL
Ascendis Pharma A/S
ASND
$16.3B
$29.7M 2.83%
+447,000
New +$29.4M
RCUS icon
12
Arcus Biosciences
RCUS
$3.72B
$27.4M 2.61%
2,236,387
– –
UBX
13
DELISTED
Unity Biotechnology
UBX
$25.3M 2.41%
+168,064
New +$24.6M
KZR
14
DELISTED
Kezar Life Sciences
KZR
$22M 2.1%
+127,220
New +$22.2M
KYNB
15
CALL
Kyntra Bio
KYNB
$32.5M
$21.9M 2.09%
14,000
+1,000
+8% +$1.3M
SGMO
16
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$21.4M 2.04%
+1,509,671
New +$25.1M
DNTH icon
17
Dianthus Therapeutics
DNTH
$5.92B
$20.8M 1.98%
+96,131
New +$21.7M
GILD icon
18
CALL
Gilead Sciences
GILD
$181B
$20.7M 1.97%
+292,600
New +$20.7M
IMDZ
19
DELISTED
Immune Design Corp.
IMDZ
$20.2M 1.92%
4,437,600
– –
WVE icon
20
Wave Life Sciences
WVE
$993M
$15.8M 1.5%
412,871
-1,046,201
-72% -$45M
SURF
21
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$14.5M 1.38%
+890,808
New +$12.9M
EIGR
22
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$12.7M 1.21%
+34,650
New +$12.3M
IRWD icon
23
CALL
Ironwood Pharmaceuticals
IRWD
$682M
$11M 1.05%
689,654
-107,699
-14% -$1.59M
ACHN
24
DELISTED
Achillion Pharmaceuticals
ACHN
$11M 1.05%
3,887,407
+219,100
+6% +$746K
KDMN
25
DELISTED
Kadmon Holdings, Inc.
KDMN
$9.97M 0.95%
+2,500,000
New +$9.76M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2018 Portfolio in Review

As of Q2 2018, EcoR1 Capital held 48 positions worth $1.05B, up 5.4% from $997M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

EcoR1 Capital withdrew a net $44.1M in Q2 2018, closing 15 positions and reducing 6 holdings. Its most notable exit was Array Biopharma Inc, an estimated $49.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 94% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Scholar Rock worth $41.7M.

  • EcoR1 Capital's largest Q2 2018 buy was Scholar Rock: 2,671,161 shares worth $41.7M.
  • EcoR1 Capital added most to Ironwood Pharmaceuticals in Q2 2018, an estimated $6.44M increase.
  • EcoR1 Capital's biggest Q2 2018 reduction was Wave Life Sciences, cutting an estimated $45M.
  • EcoR1 Capital fully exited Array Biopharma Inc in Q2 2018, selling an estimated $49.8M.
  • EcoR1 Capital's ten largest holdings make up 70% of its $1.05B portfolio in Q2 2018.
  • EcoR1 Capital opened 17 new positions and closed 15 in Q2 2018.
  • EcoR1 Capital's portfolio value rose 5.4% quarter-over-quarter to $1.05B.

Based on EcoR1 Capital's 13F filing for Q2 2018, filed 14 Aug 2018.